Categories: News

InnovAge to Announce Fiscal First Quarter 2022 Financial Results and Host Conference Call Tuesday, November 9, 2021

DENVER, Oct. 19, 2021 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal first quarter financial results on Tuesday, November 9, 2021, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T.

Conference Call Details
The conference call can be accessed by dialing (833) 398-1024 for U.S. participants, or (914) 987-7722 for international participants, and referencing participant code 8193149. A live audio webcast will be available online at https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 12 months.

About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors. Our mission is to enable seniors to age independently in their own homes for as long as possible. Our patient-centered care model meaningfully improves the quality of care our participants receive, while reducing over-utilization of high-cost care settings. InnovAge is at the forefront of value based senior healthcare and directly contracts with government payors, such as Medicare and Medicaid, to manage the totality of a participant’s medical care. InnovAge believes its healthcare model is one in which all constituencies – participants, their families, providers and government payors – “win.” InnovAge served approximately 6,850 participants across 18 centers in five states as of June 30, 2021.

Investor Contact:
Ryan Kubota
rkubota@myinnovage.com

Media Contact:
Kyle Evans
Kyle.Evans@westwicke.com

Staff

Recent Posts

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

3 hours ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

5 hours ago

ITRI Opens CES 2025 With Trend-Leading Showcase and Partnership With Reliance Biotech Corporation

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) initiated its presence…

5 hours ago

NOTICE OF DATA BREACH

LOS ANGELES, Jan. 8, 2025 /PRNewswire/ -- Dear members of the STIIIZY community:  Stiiizy, Inc.…

5 hours ago

Ascent Strategy Group Recognized by Modern Healthcare’s Best in Business, Affirms Health Equity Mission Amid Alarming Disparities

Agency Founder nominated Outstanding Agency Professional, Innovator of the Year First public relations agency built…

5 hours ago

Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or…

8 hours ago